Anixa Biosciences Inc. (CY71)
XMUN 
Summary
CY71 Chart
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Anixa Biosciences Inc. Dividends
Anixa Biosciences Inc. Earnings
| 6 Jun 2025 Date | | - Cons. EPS | - EPS |
| 21 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Sep 2024 Date | | - Cons. EPS | - EPS |
| 4 Jun 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 6 Jun 2025 Date | | - Cons. EPS | - EPS |
| 21 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Sep 2024 Date | | - Cons. EPS | - EPS |
| 4 Jun 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
Anixa Biosciences Inc. (CY71) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anixa Biosciences Inc. ever had a stock split?
Anixa Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Amit Kumar Ph.D. CEO | XMUN Exchange | US03528H1095 ISIN |
| US Country | 5 Employees | - Last Dividend | 26 Jun 2015 Last Split | 1 Jan 1987 IPO Date |
Overview
Anixa Biosciences, Inc. is a pioneering biotechnology enterprise committed to the innovation of novel treatments and vaccines addressing the urgent needs within oncology and infectious diseases sectors. Since its inception in 1982 and formerly known as ITUS Corporation before rebranding in October 2018, Anixa has been at the forefront of developing groundbreaking therapies. Headquartered in San Jose, California, the company concentrates on leveraging advancements in science and technology to create solutions for diseases with significant unmet medical needs, particularly focusing on various forms of cancer.
Products and Services
- Chimeric Endocrine Receptor T-Cell Therapy
This novel form of chimeric antigen receptor T-cell (CAR-T) technology is under development by Anixa Biosciences with a primary focus on treating ovarian cancer. By tailoring the body's own immune cells to better recognize and fight cancer, this therapy represents a promising advance in personalized medicine for ovarian cancer patients.
- Vaccine Against Triple Negative Breast Cancer
An innovative project undertaken by Anixa is the development of a vaccine aimed at combating triple negative breast cancer. This form of breast cancer is particularly challenging to treat due to the lack of hormone receptors, which are typically targeted in other breast cancer treatments. Anixa's vaccine seeks to stimulate the immune system to prevent or treat this aggressive type of cancer.
- Preventative Vaccine Against Ovarian Cancer
Focusing on prevention, Anixa is also working on a vaccine aimed at ovarian cancer, one of the most deadly forms of gynecological cancer. The goal of this vaccine is to train the immune system to recognize and eliminate cells that could potentially develop into cancer, thus offering a prophylactic solution to high-risk individuals.
- Immuno-Therapy Drugs Against Cancer
Aside from vaccines and targeted cell therapies, Anixa Biosciences is also developing a range of immuno-therapy drugs designed to empower the immune system in fighting against cancer. These drugs work by various mechanisms to enhance the body's natural defense systems, showing promise in treating different types of cancer.
Contact Information
